CN105636961B - 哌嗪衍生物及其作为药物的用途 - Google Patents
哌嗪衍生物及其作为药物的用途 Download PDFInfo
- Publication number
- CN105636961B CN105636961B CN201480056368.8A CN201480056368A CN105636961B CN 105636961 B CN105636961 B CN 105636961B CN 201480056368 A CN201480056368 A CN 201480056368A CN 105636961 B CN105636961 B CN 105636961B
- Authority
- CN
- China
- Prior art keywords
- mmol
- hplc
- title compound
- sup
- give
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13188904 | 2013-10-16 | ||
| EP13188904.0 | 2013-10-16 | ||
| PCT/EP2014/072085 WO2015055698A1 (en) | 2013-10-16 | 2014-10-15 | Piperazine derivatives and the use thereof as medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105636961A CN105636961A (zh) | 2016-06-01 |
| CN105636961B true CN105636961B (zh) | 2019-11-05 |
Family
ID=49354583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480056368.8A Active CN105636961B (zh) | 2013-10-16 | 2014-10-15 | 哌嗪衍生物及其作为药物的用途 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9233953B2 (https=) |
| EP (1) | EP3057963B1 (https=) |
| JP (1) | JP6483105B2 (https=) |
| KR (1) | KR102281284B1 (https=) |
| CN (1) | CN105636961B (https=) |
| AR (1) | AR098037A1 (https=) |
| AU (1) | AU2014336258B2 (https=) |
| BR (1) | BR112016008062B1 (https=) |
| CA (1) | CA2926754C (https=) |
| CL (1) | CL2016000884A1 (https=) |
| DK (1) | DK3057963T3 (https=) |
| EA (1) | EA029313B1 (https=) |
| ES (1) | ES2745555T3 (https=) |
| HU (1) | HUE047044T2 (https=) |
| IL (1) | IL244693B (https=) |
| MX (1) | MX370006B (https=) |
| PH (1) | PH12016500577B1 (https=) |
| PL (1) | PL3057963T3 (https=) |
| TW (1) | TW201609716A (https=) |
| UY (1) | UY35785A (https=) |
| WO (1) | WO2015055698A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106854189A (zh) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | 一种哌嗪化合物的合成方法 |
| CN107778257A (zh) * | 2016-08-29 | 2018-03-09 | 湖南华腾制药有限公司 | 一种哌嗪衍生物的合成方法 |
| CN106977463A (zh) * | 2017-05-31 | 2017-07-25 | 湖南华腾制药有限公司 | 一种联苯取代哌嗪衍生物的合成方法 |
| CN107417679A (zh) * | 2017-08-04 | 2017-12-01 | 河南农业大学 | 1,3‑唑类取代吡嗪类化合物的制备方法 |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| CN117050051A (zh) * | 2023-08-14 | 2023-11-14 | 上海药坦药物研究开发有限公司 | 一种2-溴-1-（5-碘噻吩-2-基）-乙酮的纯化方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035556A1 (en) * | 2002-10-16 | 2004-04-29 | Glaxo Group Limited | Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists |
| WO2006094840A1 (en) * | 2005-03-11 | 2006-09-14 | Glaxo Group Limited | Compounds |
| WO2006113704A2 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| WO2011003418A1 (en) * | 2009-07-08 | 2011-01-13 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
-
2014
- 2014-10-14 US US14/513,918 patent/US9233953B2/en active Active
- 2014-10-15 CA CA2926754A patent/CA2926754C/en active Active
- 2014-10-15 EA EA201600323A patent/EA029313B1/ru not_active IP Right Cessation
- 2014-10-15 KR KR1020167012860A patent/KR102281284B1/ko active Active
- 2014-10-15 MX MX2016004847A patent/MX370006B/es active IP Right Grant
- 2014-10-15 JP JP2016523968A patent/JP6483105B2/ja active Active
- 2014-10-15 AR ARP140103834A patent/AR098037A1/es unknown
- 2014-10-15 AU AU2014336258A patent/AU2014336258B2/en active Active
- 2014-10-15 ES ES14784235T patent/ES2745555T3/es active Active
- 2014-10-15 WO PCT/EP2014/072085 patent/WO2015055698A1/en not_active Ceased
- 2014-10-15 TW TW103135739A patent/TW201609716A/zh unknown
- 2014-10-15 EP EP14784235.5A patent/EP3057963B1/en active Active
- 2014-10-15 BR BR112016008062-9A patent/BR112016008062B1/pt active IP Right Grant
- 2014-10-15 PL PL14784235T patent/PL3057963T3/pl unknown
- 2014-10-15 CN CN201480056368.8A patent/CN105636961B/zh active Active
- 2014-10-15 DK DK14784235.5T patent/DK3057963T3/da active
- 2014-10-15 HU HUE14784235A patent/HUE047044T2/hu unknown
- 2014-10-16 UY UY0001035785A patent/UY35785A/es unknown
-
2016
- 2016-03-21 IL IL244693A patent/IL244693B/en active IP Right Grant
- 2016-03-30 PH PH12016500577A patent/PH12016500577B1/en unknown
- 2016-04-14 CL CL2016000884A patent/CL2016000884A1/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035556A1 (en) * | 2002-10-16 | 2004-04-29 | Glaxo Group Limited | Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists |
| WO2006094840A1 (en) * | 2005-03-11 | 2006-09-14 | Glaxo Group Limited | Compounds |
| WO2006113704A2 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| WO2011003418A1 (en) * | 2009-07-08 | 2011-01-13 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| "Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]- [5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia";Emmanuel Pinard，等;《J. Med. Chem.》;20100521;第53卷(第12期);第4603-4614页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016500577A1 (en) | 2016-06-20 |
| NZ718251A (en) | 2021-02-26 |
| CN105636961A (zh) | 2016-06-01 |
| KR20160062187A (ko) | 2016-06-01 |
| PL3057963T3 (pl) | 2019-12-31 |
| KR102281284B1 (ko) | 2021-07-23 |
| US20150105397A1 (en) | 2015-04-16 |
| HUE047044T2 (hu) | 2020-04-28 |
| MX2016004847A (es) | 2016-07-19 |
| TW201609716A (zh) | 2016-03-16 |
| EA201600323A1 (ru) | 2016-10-31 |
| CA2926754C (en) | 2021-09-14 |
| WO2015055698A1 (en) | 2015-04-23 |
| UY35785A (es) | 2015-04-30 |
| IL244693A0 (en) | 2016-04-21 |
| AU2014336258B2 (en) | 2018-07-12 |
| DK3057963T3 (da) | 2019-09-16 |
| US9233953B2 (en) | 2016-01-12 |
| CL2016000884A1 (es) | 2016-12-30 |
| CA2926754A1 (en) | 2015-04-23 |
| EA029313B1 (ru) | 2018-03-30 |
| JP6483105B2 (ja) | 2019-03-13 |
| PH12016500577B1 (en) | 2016-06-20 |
| IL244693B (en) | 2019-08-29 |
| AU2014336258A1 (en) | 2016-04-14 |
| AR098037A1 (es) | 2016-04-27 |
| BR112016008062A2 (https=) | 2017-08-01 |
| EP3057963B1 (en) | 2019-06-19 |
| ES2745555T3 (es) | 2020-03-02 |
| JP2016533368A (ja) | 2016-10-27 |
| BR112016008062B1 (pt) | 2022-11-16 |
| EP3057963A1 (en) | 2016-08-24 |
| MX370006B (es) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI855062B (zh) | Bcl-2抑制劑 | |
| CN103797005B (zh) | 苯基-3-氮杂-双环[3.1.0]己-3-基-甲酮及其作为药物的用途 | |
| CN101305011B (zh) | 吡啶衍生物及其在治疗精神障碍中的用途 | |
| CN110248939B (zh) | 作为rho-激酶抑制剂的酪氨酸酰胺衍生物 | |
| CN105636961B (zh) | 哌嗪衍生物及其作为药物的用途 | |
| JP6609631B2 (ja) | 縮合環ヘテロアリール化合物及びｔｒｋ抑制剤としての用途 | |
| JP7720864B2 (ja) | ハンチントン病を処置するためのｈｔｔモジュレータ | |
| CN111491930A (zh) | 可用作tlr抑制剂的经取代的吲哚化合物 | |
| TW201615642A (zh) | 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物 | |
| CN100389115C (zh) | 吡啶氧基甲基和苯并异唑氮杂二环衍生物 | |
| WO2006033318A1 (ja) | 環状アミン誘導体又はその塩 | |
| CN108137602B (zh) | 吡唑并[1,5-a]嘧啶-3-甲酰胺的环醚衍生物 | |
| CN114787136A (zh) | 经取代的苯并咪唑甲酰胺及其在治疗医学病症中的用途 | |
| AU2023313330A1 (en) | Novel sulfonamides and their use as neuroprotective and/or neurorestorative agents | |
| JP2025525081A (ja) | 新規スルホン並びに神経保護剤及び／又は神経修復剤としてのその使用 | |
| HK1193100B (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| HK40012938A (en) | Tyrosine amide derivatives as rho- kinase inhibitors | |
| HK1242307A1 (en) | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors | |
| HK1242314A1 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| HK1085725B (en) | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | |
| HK1242314B (zh) | 稠环杂芳基化合物及其作为trk抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |